Drugs for Cognitive Loss and Dementia | The Medical Letter Inc.

Treatment Guidelines from The Medical Letter

FROM
ISSUE

134

October 1, 2013

View Complete Issue Table of Contents 2019

Drugs for Cognitive Loss and Dementia

Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article.

Drugs for Cognitive Loss and Dementia

October 1, 2013 (Issue: 134)

Superseded by The Medical Letter "Drugs for Cognitive Loss and Dementia" - Issue 1657, August 22, 2022

Alzheimer's disease (AD) is the most common cause of dementia, but cognitive loss is also associated with other neurological conditions such as Parkinson's disease, dementia with Lewy bodies, and vascular dementia. Mild cognitive impairment (MCI)...more

Show References Hide References

1. MS Albert et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7:270.

2. SS Gill et al. Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors. A population-based cohort study. Arch Intern Med 2009; 169:867.

3. Donepezil (Aricept) for Alzheimer's disease. Med Lett Drugs Ther 1997; 39:53.

4. RC Petersen et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 2005; 352:2379.

5. RS Doody et al. Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial. Neurology 2009; 72:1555.

6. B Winblad et al. Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study. Lancet 2006; 367:1057.

7. SE Black et al. Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology 2007; 69:459.

8. R Howard et al. Donepezil and memantine for moderate-to-severe Alzheimer's disease. N Engl J Med 2012; 366:893.

9. RJ Howard et al. Donepezil for the treatment of agitation in Alzheimer's disease. N Engl J Med 2007; 357:1382.

10. M Rolinski et al. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease. Cochrane Database Syst Rev 2012; (3):CD006504.

11. E Mori et al. Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled trial. Ann Neurol 2012; 72:41.

12. D Wilkinson et al. Donepezil in vascular dementia: a randomized, placebo-controlled study. Neurology 2003; 61:479.

13. GC Román et al. Randomized, placebo-controlled, clinical trial of donepezil in vascular dementia: differential effects by hippocampal size. Stroke 2010; 41:1213.

14. MR Farlow et al. Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: a 24-week, randomized, double-blind study. Clin Ther 2010; 32:1234.

15. DS Knopman. Donepezil 23 mg: An empty suit. Neurol Clin Pract 2012; 2:352.

16. Inhibitors and inducers of CYP enzymes and P-glycoprotein. Med Lett Drugs Ther 2013; 55:e44.

17. Galantamine (Reminyl) for Alzheimer's disease. Med Lett Drugs Ther 2001; 43:53.

18. B Winblad et al. Safety and efficacy of galantamine in subjects with mild cognitive impairment. Neurology 2008; 70:2024.

19. T Erkinjuntti et al. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet 2002; 359:1283.

20. R Bullock et al. Management of patients with Alzheimer's disease plus cerebrovascular disease: 12-month treatment with galantamine. Dement Geriatr Cogn Disord 2004; 17:29.

21. Rivastigmine (Exelon) for Alzheimer's disease. Med Lett Drugs Ther 2000; 42:93.

22. J Birks et al. Rivastigmine for Alzheimer's disease. Cochrane Database Syst Rev 2009; (2): CD001191.

23. B Winblad et al. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease – rivastigmine patch versus capsule. Int J Geriatr Psychiatry 2007; 22:456.

24. MR Farlow et al. A 24-week, randomized, controlled trial of rivastigmine patch 13.3 mg/24 h versus 4.6 mg/24 h in severe Alzheimer's dementia. CNS Neurosci Ther 2013 Aug 7 (epub).

25. M Emre et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004; 351:2509.

26. I McKeith et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000; 356:2031.

27. A Wentrup et al. Once-daily transdermal rivastigmine in the treatment of Alzheimer's disease. Drug Des Devel Ther 2008; 2:245.

28. J Cummings et al. Randomized, double-blind, parallel-group, 48-week study for efficacy and safety of a higher-dose rivastigmine patch (15 vs 10 cm2) in Alzheimer's disease. Dement Geriatr Cogn Disord 2012; 33:341.

29. Memantine for Alzheimer's disease. Med Lett Drugs Ther 2003; 45:73.

30. PT Francis et al. Rationale for combining glutamatergic and cholinergic approaches in the symptomatic treatment of Alzheimer's disease. Expert Rev Neurother 2012; 12:1351.

31. B Reisberg et al. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003; 348:1333.

32. PN Tariot et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004; 291:317.

33. GT Grossberg et al. The safety, tolerability and efficacy of once-daily memantine (28 mg): A multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer's disease taking cholinesterase inhibitors. CNS Drugs 2013; 27:469.

34. AP Porsteinsson et al. Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double blind, placebo-controlled trial. Curr Alzheimer Res 2008; 5:83.

35. JM Orgogozo et al. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). Stroke 2002; 33:1834.

36. G Wilcock et al. A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). Int Clin Psychopharmacol 2002; 17:297.

37. M Emre et al. Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010; 9:969.

38. DV Jeste et al. ACNP White Paper: update on use of antipsychotic drugs in elderly persons with dementia. Neuropsychopharmacology 2008; 33:957.

39. DL Sultzer et al. Clinical symptom responses to atypical antipsychotioc medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial. Am J Psychiatry 2008; 165:844.

40. CL Vigen et al. Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD. Am J Psychiatry 2011; 168:831.

41. Drugs for psychiatric disorders. Treat Guidel Med Lett 2013; 11:53.

42. HC Liu et al. Extrapyramidal side-effect due to drug combination of risperidone and donepezil. Psychiatry Clin Neurosci 2002; 56:479.

43. ST DeKosky et al. Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA 2008; 300:2253.

44. LS Schneider et al. A randomized, double-blind, placebo-controlled trial of two doses of Ginko biloba extract in dementia of the Alzheimer's type. Curr Alzheimer Res 2005; 2:541.

45. BE Snitz et al. Ginkgo biloba for preventing cognitive decline in older adults: a randomized trial. JAMA 2009; 302:2663.

46. A medical food for Alzheimer's disease. Med Lett Drugs Ther 2009; 51:49.

47. P Thaipisuttikul and JE Galvin. Use of medical foods and nutritional approaches in the treatment of Alzheimer's disease. Clin Pract (Lond) 2012; 9:199.

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.